Skip to main content

Finding secular growth stories – those stocks representing above-average revenue and profit growth and with high probabilities of continuing market-beating growth in the future – is the holy grail of equity markets. Companies capable of sustaining strong growth paths without the help of falling interest rates or strong global economic growth are particularly attractive in the current period of market volatility.

Thankfully, the research team at Morgan Stanley recently released its 25 top picks of secular growth stocks for the next two years.

The research team defines secular growth companies as those it believes “can deliver strong growth, driven by forces such as sustainable competitive advantages, product cycles, market share gains, or pricing power.”

Story continues below advertisement

The methodology for uncovering the best opportunities started by identifying companies that have generated positive revenue growth for each of the past 12 quarters. Within that group, the analysts screened for stocks where average annual earnings growth for the 2017 to 2020 period is forecast above 15 per cent and revenues were predicted to improve by at least 10 per cent a year. (The report made allowances for cases where analysts had particularly high conviction on a stock, which I think explains why four of the 25 stocks fall below the 10-per-cent threshold for revenue growth.)

The resulting list is shown in the accompanying table. It includes some of the usual suspects such as technology giants Amazon.com Inc., Alphabet Inc., Salesforce.com Inc., and credit card companies Mastercard Inc. and Visa Inc. Surprises include cosmetics retailer Ulta Beauty Inc., instructional software provider Pluralsight Inc. and animal health product manufacturer Zoetis Inc.

Morgan Stanley top picks for secular growth stocks

Company Symbol Revenue CAGR 2017-2020(est) EPS CAGR 2017-2020(est) Price/2017 EPS (diluted) Price/2019 EPS(est) (diluted)
Atlassian Corp. Plc-Class A TEAM-Q 31.1 35.2 174.4 89.7
Biomarin Pharmaceutical Inc. BMRN-Q 18.6 73.2 209.8 89.4
Workday Inc.-Class A WDAY-Q 25.7 39.0 114.2 72.2
Netflix Inc. NFLX-Q 26.8 71.5 153.6 69.7
ServiceNow Inc. NOW-N 30.0 50.1 96.9 54.3
Veeva Systems Inc.-Class A VEEV-N 20.0 26.9 64.8 54.3
Amazon.com Inc. AMZN-Q 23.3 96.8 190.1 51.3
National Vision Holdings Inc. EYE-Q 10.9 20.7 76.6 48.3
Illumina Inc. ILMN-Q 20.1 27.4 54.5 46.4
Salesforce.com Inc. CRM-N 22.1 34.3 68.8 44.3
Vertex Pharmaceuticals Inc. VRTX-Q 25.2 58.0 76.7 41.7
Intuitive Surgical Inc. ISRG-Q 17.2 20.5 40.6 38.5
Adobe Inc. ADBE-Q 19.9 30.1 42.0 29.3
Palo Alto Networks Inc. PANW-N 24.7 32.5 50.9 27.9
Visa Inc.-Class A Shares V-N 10.9 20.9 30.2 25.7
Mastercard Inc. - A MA-N 14.5 24.1 33.1 25.5
Zoetis Inc. ZTS-N 9.0 18.4 30.0 25.1
Ulta Beauty Inc. ULTA-Q 12.6 21.4 26.7 23.6
Alphabet Inc.-Cl A GOOGL-Q 21.3 45.8 58.3 23.5
Iqvia Holdings Inc. IQV-N 6.0 15.7 21.5 19.1
Expedia Group Inc. EXPE-Q 9.3 19.2 27.8 17.4
Booking Holdings Inc. BKNG-Q 14.0 15.9 22.5 17.2
Regeneron Pharmaceuticals REGN-Q 9.5 15.7 23.0 16.0
Assurant Inc. AIZ-N 18.4 36.5 25.6 11.9
Pluralsight Inc. - A PS-Q 34.4 N/A N/A N/A

Source: Morgan Stanley

CAGR = compound annual growth rate.

Three companies caught my attention as potential sources for further research – Illumina Inc., Intuitive Surgical Inc., and Palo Alto Networks Inc. Each company appears fairly valued at first glance in light of expected growth rates and situated in industries – health care and network security – with clear tailwinds.

Morgan Stanley describes Illumina as “the dominant provider of technology to sequence DNA” and is set to benefit from increases in corporate and government investment in DNA analysis. Consumer interest in DNA testing continues to climb with a 300-per-cent increase in DNA-related orders for Illumina over the past two years.

Intuitive Surgical builds robots that perform surgery. The analysts say the company “has gained significant adoption within urology and gynecology and is still in the relatively early stages of penetration internationally and within broader procedures."

Palo Alto Networks develops software to protect information networks from hacking. The volume of high profile network security issues in recent years, combined with the growth of “big data” operations that collect and analyze huge amounts of information, implies that demand for Palo Alto software will continue for the foreseeable future.

Morgan Stanley provides a plausible growth story for each of the 25 stocks in the table, but that does not mean these investments are without risk.

Story continues below advertisement

In many cases, a company’s growth has already been recognized by the market and the stocks are trading at extreme valuation levels. Atlassian Corp. and Biomarin Pharmaceuticals Inc., for instance, are both trading close to 90 times 2019 earnings estimates. The analysts could be correct in predicting continued profit growth, but there is no guarantee that valuation levels will stay the same. A fall in price-to-earnings ratios to more reasonable levels would come at the expense of the stock price even if growth estimates proved accurate.

Scott Barlow, Globe Investor’s in-house market strategist, writes exclusively for our subscribers at Inside the Market.

Report an error Editorial code of conduct
Tickers mentioned in this story
Unchecking box will stop auto data updates
Comments

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • All comments will be reviewed by one or more moderators before being posted to the site. This should only take a few moments.
  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed. Commenters who repeatedly violate community guidelines may be suspended, causing them to temporarily lose their ability to engage with comments.

Read our community guidelines here

Discussion loading ...

Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.
Cannabis pro newsletter